IE40794B1 - Influenza vaccines - Google Patents
Influenza vaccinesInfo
- Publication number
- IE40794B1 IE40794B1 IE59/75A IE5975A IE40794B1 IE 40794 B1 IE40794 B1 IE 40794B1 IE 59/75 A IE59/75 A IE 59/75A IE 5975 A IE5975 A IE 5975A IE 40794 B1 IE40794 B1 IE 40794B1
- Authority
- IE
- Ireland
- Prior art keywords
- influenza
- components
- virus
- type
- cationic detergent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4‹C to 37‹C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.
[GB1498261A]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH44774A CH589453A5 (en) | 1974-01-14 | 1974-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE40794L IE40794L (en) | 1975-07-14 |
IE40794B1 true IE40794B1 (en) | 1979-08-15 |
Family
ID=4187233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE59/75A IE40794B1 (en) | 1974-01-14 | 1975-01-13 | Influenza vaccines |
Country Status (27)
Country | Link |
---|---|
JP (2) | JPS58407B2 (en) |
AT (1) | AT345449B (en) |
AU (1) | AU500250B2 (en) |
BE (1) | BE824372A (en) |
CA (1) | CA1049406A (en) |
CH (1) | CH589453A5 (en) |
CS (1) | CS191254B2 (en) |
DD (1) | DD116239A5 (en) |
DE (1) | DE2500785B2 (en) |
DK (1) | DK140003B (en) |
ES (1) | ES433759A1 (en) |
FI (1) | FI54053C (en) |
FR (1) | FR2257305B1 (en) |
GB (1) | GB1498261A (en) |
HK (1) | HK56380A (en) |
HU (1) | HU173920B (en) |
IE (1) | IE40794B1 (en) |
IL (1) | IL46426A (en) |
MY (1) | MY8100204A (en) |
NL (1) | NL166622C (en) |
NO (1) | NO143128C (en) |
PH (1) | PH14458A (en) |
PL (1) | PL93689B1 (en) |
SE (1) | SE427238B (en) |
SU (1) | SU616997A3 (en) |
YU (1) | YU41289B (en) |
ZA (1) | ZA75259B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2829089A1 (en) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | SUBUNIT VACCINE |
JPH0688911B2 (en) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | Influenza vaccine and method for producing the same |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
EP0919243A1 (en) | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
DE19938767C2 (en) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | subunit vaccines |
ES2359214T5 (en) * | 2005-11-01 | 2014-10-08 | Novartis Vaccines And Diagnostics Gmbh | Viral vaccines derived from cells with reduced levels of residual cellular DNA by treatment with beta-propiolactone |
SI2192917T1 (en) * | 2007-08-28 | 2014-05-30 | Baxter International Inc. | Method for producing viral vaccines |
EP3068791B1 (en) | 2013-11-15 | 2020-07-29 | Novartis AG | Removal of residual cell culture impurities |
-
1974
- 1974-01-14 CH CH44774A patent/CH589453A5/xx not_active IP Right Cessation
-
1975
- 1975-01-06 NO NO750031A patent/NO143128C/en unknown
- 1975-01-06 FI FI750014A patent/FI54053C/en not_active IP Right Cessation
- 1975-01-06 DK DK1475AA patent/DK140003B/en not_active IP Right Cessation
- 1975-01-07 SE SE7500130A patent/SE427238B/en not_active IP Right Cessation
- 1975-01-10 NL NL7500301.A patent/NL166622C/en not_active IP Right Cessation
- 1975-01-10 DE DE2500785A patent/DE2500785B2/en active Granted
- 1975-01-13 DD DD183614A patent/DD116239A5/xx unknown
- 1975-01-13 AT AT21475A patent/AT345449B/en not_active IP Right Cessation
- 1975-01-13 YU YU58/75A patent/YU41289B/en unknown
- 1975-01-13 HU HU75SA2736A patent/HU173920B/en not_active IP Right Cessation
- 1975-01-13 GB GB1290/75A patent/GB1498261A/en not_active Expired
- 1975-01-13 PH PH16702A patent/PH14458A/en unknown
- 1975-01-13 IE IE59/75A patent/IE40794B1/en unknown
- 1975-01-13 ES ES433759A patent/ES433759A1/en not_active Expired
- 1975-01-13 IL IL46426A patent/IL46426A/en unknown
- 1975-01-13 PL PL1975177303A patent/PL93689B1/pl unknown
- 1975-01-13 CA CA217,790A patent/CA1049406A/en not_active Expired
- 1975-01-14 BE BE152368A patent/BE824372A/en not_active IP Right Cessation
- 1975-01-14 FR FR7501007A patent/FR2257305B1/fr not_active Expired
- 1975-01-14 JP JP50006975A patent/JPS58407B2/en not_active Expired
- 1975-01-14 ZA ZA00750259A patent/ZA75259B/en unknown
- 1975-01-14 CS CS75255A patent/CS191254B2/en unknown
- 1975-01-14 SU SU752101722A patent/SU616997A3/en active
- 1975-01-14 AU AU77305/75A patent/AU500250B2/en not_active Expired
-
1980
- 1980-10-09 HK HK563/80A patent/HK56380A/en unknown
-
1981
- 1981-01-29 JP JP56012831A patent/JPS6035326B2/en not_active Expired
- 1981-12-30 MY MY204/81A patent/MY8100204A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2121241A1 (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
IE40794L (en) | Influenza vaccine. | |
KR850001700A (en) | Method for preparing Herpes Simplex Virus Subuait Vaccine | |
US3674864A (en) | Process for stabilizing preparations of interfering viruses | |
Kurrle et al. | Influenza virus‐specific T cell‐mediated cytotoxicity: integration of the virus antigen into the target cell membrane is essential for target cell formation | |
Bang | Filamentous forms of Newcastle virus | |
GB1183506A (en) | New vaccines for combating influenza and the preparation thereof | |
IE781880L (en) | Immunogenic herpes virus subunit | |
ES8203225A1 (en) | Process for isolating viral glycoproteic antigens, and its use in the preparation of vaccines. | |
ES471615A1 (en) | Glycoproteins from paramyxovirus and vaccines therefrom | |
IE40180B1 (en) | Influenza virus vaccines and preparation thereof | |
AU2004249802B2 (en) | Improvements in virus production | |
Mims | Rift Valley fever virus in mice. II. Adsorption and multiplication of virus | |
Russell et al. | Mumps Viral Cytolysin: I. Action on Human Epithelial Cells in Tissue Culture | |
AU5573196A (en) | A pluripotent vaccine against enveloped viruses | |
GB660109A (en) | Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine | |
GB1016586A (en) | Vaccine for immunization of dogs against distemper and hepatitis contagiosa canis | |
JP2841592B2 (en) | Virus particle disruption method | |
Danes et al. | Study of the possibility of preparing a vaccine against tick-borne encephalitis, using tissue culture methods. II. The inactivation by formaldehyde of the tickborne encephalitis virus in liquids prepared from tissue cultures. Immunogenic properties | |
GB1434181A (en) | Vaccine for the prevention and treatment of vascular conditions | |
GB777018A (en) | Poliomyelitis vaccine products and methods for preparing the same | |
郭元吉 et al. | Influenza C virus isolated from pigs in China | |
AR120296A1 (en) | CHIKUNGUNYA-TYPE VIRUS PARTICLE VACCINE AND ITS METHODS OF USE | |
ES379053A3 (en) | Procedure for the preparation of antiviric vaccines. (Machine-translation by Google Translate, not legally binding) | |
USD138000S (en) | Design for a toy landing barge |